Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
Chen HJ, Tu HY, Hu Y, Fan Y, Wu G, Cang S, Yang Y, Yang N, Ma R, Jin G, Xu X, Liu A, Tang S, Cheng Y, Yu Y, Xu CR, Zhou Q, Wu YL. Chen HJ, et al. Among authors: yang n, yang y. J Hematol Oncol. 2025 Jan 5;18(1):3. doi: 10.1186/s13045-024-01656-0. J Hematol Oncol. 2025. PMID: 39757186 Free PMC article. Clinical Trial.
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.
Guo LH, Zhang MF, Zhang HL, Zhou JY, Cai XH, Long Y, Guo QS, Yang N, Zhao J, Xie ZH, Jiang B, Zhu Y, Fan Y, Xie CY, Hu Y, Yao Y, Jia J, Li XL, Cui JW, Sui XZ, Lin W, Cheng Y, Wang HJ, Wang CL, Zhao MF, Qiao GB, Peng LJ, Yang L, Chen GY, Cai KC, Xu XH, Zhang LM, Feng GS, Zhou JM, Wu GW, Dong XR, Wang LF, Zhang HM, Gao YJ, Jiang QY, Cang SD, Yang ZX, Song X, Liu XQ, Zhu B, Chen FX, Hu CH, Chen X, Wu YL, Zhou Q. Guo LH, et al. Among authors: yang zx, yang l, yang n. Front Oncol. 2020 Sep 15;10:1568. doi: 10.3389/fonc.2020.01568. eCollection 2020. Front Oncol. 2020. PMID: 33042801 Free PMC article.
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N. Wang J, et al. Among authors: yang k, yang n. JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. JAMA Oncol. 2021. PMID: 33792623 Free PMC article. Clinical Trial.
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Zhou Q, et al. Among authors: yang jj, yang n. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12. Cancer Cell. 2021. PMID: 34388377 Free article. Clinical Trial.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Among authors: yang n, yang j. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
Zhou Q, Meng X, Sun L, Huang D, Yang N, Yu Y, Zhao M, Zhuang W, Guo R, Hu Y, Pan Y, Shan J, Sun M, Yuan Y, Fan Y, Huang J, Liu L, Chu Q, Wang X, Xu C, Lin J, Huang J, Huang M, Sun J, Zhang S, Zhou H, Wu YL. Zhou Q, et al. Among authors: yang n. J Thorac Oncol. 2024 Dec;19(12):1630-1639. doi: 10.1016/j.jtho.2024.08.005. Epub 2024 Aug 9. J Thorac Oncol. 2024. PMID: 39127176 Clinical Trial.
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, Fan Y, Shi J, Zhang G, Cui J, Zhou J, Song Y, Zhuang W, Ma Z, Hu Y, Li G, Dong X, Feng J, Lu S, Wu J, Li J, Zhang L, Wang D, Xu X, Yang TY, Yang N, Guo Y, Zhao J, Yao Y, Zhong D, Xia B, Yang CT, Zhu B, Sun P, Shim BY, Chen Y, Wang Z, Ahn MJ, Wang J, Wu YL. Zhou Q, et al. Among authors: yang ty, yang ct, yang n. Med. 2025 Jan 10;6(1):100513. doi: 10.1016/j.medj.2024.09.002. Epub 2024 Oct 9. Med. 2025. PMID: 39389055 Clinical Trial.
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Wang Y, Wang L, Yang N, Zhang Y, Yu Z, Zhao Y, Xie C, Cheng Y, Zhou H, Wang S, Zhu D, Zhang W, Zhang L. Yang Y, et al. Among authors: yang n, yang z. J Thorac Oncol. 2020 Oct;15(10):1636-1646. doi: 10.1016/j.jtho.2020.07.014. Epub 2020 Aug 8. J Thorac Oncol. 2020. PMID: 32781263 Free article. Clinical Trial.
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, Liang Z, Cheng Y, Jiang L, Yang N, Han Z, Shi J, Chen Y, Xu H, Zhang H, Chen G, Ma R, Sun S, Fan Y, Li J, Luo X, Wang L, Ren Y, Su W. Lu S, et al. Among authors: yang n. Lancet Respir Med. 2021 Oct;9(10):1154-1164. doi: 10.1016/S2213-2600(21)00084-9. Epub 2021 Jun 21. Lancet Respir Med. 2021. PMID: 34166627 Clinical Trial.
A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.
Zhou Q, Wu L, Hu P, An T, Zhou J, Zhang L, Liu XQ, Luo F, Zheng X, Cheng Y, Yang N, Li J, Feng J, Han B, Song Y, Wang K, Zhang L, Fang J, Zhao H, Shu Y, Lin XY, Chen Z, Gan B, Xu WH, Tang W, Zhang X, Yang JJ, Xu X, Wu YL. Zhou Q, et al. Among authors: yang jj, yang n. Clin Cancer Res. 2022 Mar 15;28(6):1127-1135. doi: 10.1158/1078-0432.CCR-21-2595. Clin Cancer Res. 2022. PMID: 34740925 Free PMC article. Clinical Trial.
7,134 results